Who
Phillips Courtney
GC and Corp. Secretary
Company insider
Files Form 4 as: GC and Corp. Secretary, Maze Therapeutics; General Counsel & Secretary, Atreca.
In numbers
- Trades disclosed
- 35
- Buys
- 0
- Sells
- 5
- Bought
- $0
- Sold
- $227K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 11 Jul 2019
- Last trade
- 3 Sep 2026
- Last filed
- 4 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Sep 2026filed 4 Sep 2026 | MAZE Maze TherapeuticsBiotechnology | SEC FORM 4 Sold | $52K1,990 at $26.01 | filing |
| 3 Sep 2026filed 4 Sep 2026 | MAZE Maze TherapeuticsBiotechnology | SEC FORM 4 Sold | $56722 at $25.78 | filing |
| 3 Sep 2026filed 4 Sep 2026 | MAZE Maze TherapeuticsBiotechnology | SEC FORM 4 Sold | $52K1,990 at $26.01 | filing |
| 3 Sep 2026filed 4 Sep 2026 | MAZE Maze TherapeuticsBiotechnology | SEC FORM 4 Sold | $56722 at $25.78 | filing |
| 2 Sep 2026filed 4 Sep 2026 | MAZE Maze TherapeuticsBiotechnology | SEC FORM 4 Sold | $46K1,738 at $26.38 | filing |
| 2 Sep 2026filed 4 Sep 2026 | MAZE Maze TherapeuticsBiotechnology | SEC FORM 4 Sold | $6,590243 at $27.12 | filing |
| 2 Sep 2026filed 4 Sep 2026 | MAZE Maze TherapeuticsBiotechnology | SEC FORM 4 Sold | $46K1,738 at $26.38 | filing |
| 2 Sep 2026filed 4 Sep 2026 | MAZE Maze TherapeuticsBiotechnology | SEC FORM 4 Sold | $6,590243 at $27.12 | filing |
| 1 Sep 2026filed 3 Sep 2026 | MAZE Maze TherapeuticsBiotechnology | SEC FORM 4 Code M | —11,000 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | MAZE Maze Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,000 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | MAZE Maze Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,000 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | MAZE Maze TherapeuticsBiotechnology | SEC FORM 4 Code M | —11,000 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | MAZE Maze Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,000 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | MAZE Maze Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | MAZE Maze Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,000 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | MAZE Maze Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
| 22 Sep 2025filed 24 Sep 2025 | MAZE Maze Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 1 Sep 2023filed 3 Apr 2024 | Atreca | SEC FORM 4 Sold | $2,6137,061 at $0.37 | filing |
| 2 Aug 2023filed 4 Aug 2023 | Atreca | SEC FORM 4 Sold | $3,8724,076 at $0.95 | filing |
| 9 Feb 2023filed 13 Feb 2023 | Atrecaoption or derivative | SEC FORM 4 Code A | —130,000 at $0.00 | filing |
News
Maze Therapeutics (NASDAQ:MAZE) Stock Rated "Buy" in New Coverage at Canaccord Genuity GroupMAZE · themarketsdaily.com · 20 Oct 2026Head to Head Survey: Maze Therapeutics (NASDAQ:MAZE) vs. Cytokinetics (NASDAQ:CYTK)MAZE · dailypolitical.com · 18 Oct 2026
0 headlines in the last 90 days name Phillips Courtney; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.